title: Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic.
abstract: The high mortality of highly pathogenic avian influenza A (H5N1) viruses infection in humans gives rise to considerable concern that it might someday cause another lethal pandemic. At present there is no other effective alternative besides the early and enough administration of neuraminidase inhibitors, which may be crucial for the patient management. However, its efficacy is sometimes limited because of the late administration in some patients especially the seriously ill ones and the continual occurrence of oseltamivir resistant A (H5N1) strains. The specific candidate vaccine are still under development and the practical value of passive immunization is hard to be widely applied because of the scarcity of convalescent human plasma, especially in the early stage of a serious and rapidly progressing pandemic. Statins and fibrates, both of which are used in clinical practice, have anti-inflammatory and immunomodulatory effects and other multiple biologic activities. So we hypothesized that the two immunomodulatory agents may exhibit synergistic effects when they were combined to neuraminidase inhibitors to treat the A (H5N1) viruses infections via inhibiting the production of either the early inflammatory mediators (e.g., many cytokine/chemokine) or the late mediator (e.g., High Mobility Group Box Protein 1), even showing the anti-viral activities with the prevention of the development of antiviral resistance. Therefore, the novel triple combinations may be an optimal management to confront the next lethal influenza pandemic on its very beginning.
authors.affiliation: Department of Respiratory & Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Shu-Chang
authors.initials: SC
authors.lastname: An
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Xu
authors.forename: Feng-Di
authors.initials: FD
authors.lastname: Li
authors.forename: Lin-Lin
authors.initials: LL
authors.lastname: Bao
authors.forename: Chuan
authors.initials: C
authors.lastname: Qin
authors.forename: Zhan-Cheng
authors.initials: ZC
authors.lastname: Gao
mesh_terms: D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods*; D058607:Fibric Acids / Q000494:pharmacology / Q000627:therapeutic use*; D024243:HMGB1 Protein / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D053124:Influenza A Virus, H5N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D008954:Models, Biological; D009439:Neuraminidase / Q000037:antagonists & inhibitors*
chemical_list: D058607:Fibric Acids; D024243:HMGB1 Protein; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D009439:Neuraminidase